Literature DB >> 19832695

JAK3 inhibitors in organ transplantation and autoimmune disease.

Zuquan Xiong1, Anlun Ma, Huifang Chen.   

Abstract

Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase associated with the common gamma chain that is activated by multiple T-cell growth factors including IL-2, -4, -9, -15, and -21. From the recent reports, genetic absence or ablation of JAK3 is associated with defective T-cell immunity that results in severe combined immunodeficiency (SCID) and pharmacological inhibition has prolonged allograft survival in some models of organ transplantation. This review would provide an overview of some patents along with the role of JAK3 in the immune system and efficacy of JAK3 inhibitors in experimental allograft rejection and autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19832695     DOI: 10.2174/187221310789895577

Source DB:  PubMed          Journal:  Recent Pat Inflamm Allergy Drug Discov        ISSN: 1872-213X


  2 in total

1.  Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.

Authors:  Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

2.  BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway.

Authors:  Y Liu; T Yang; H Li; M-H Li; J Liu; Y-T Wang; S-X Yang; J Zheng; X-Y Luo; Y Lai; P Yang; L-M Li; Q Zou
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.